MedTrace Logo

Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

NCT07186660 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.

Conditions

  • Type 1 Diabetes (T1D)
  • Glycemic Control for Diabetes Mellitus
  • Insulin
  • Ketones
  • Cardiovascular Health

Interventions

DRUG

CIR-0602K

mitochondrial pyruvate carrier inhibitor

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • William B. Horton, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-22
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07186660 on ClinicalTrials.gov